Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) has emerged as one of the most compelling therapeutic targets in Alzheimer's disease (AD) pathogenesis. TREM2 is a transmembrane receptor primarily expressed on microglia, the immune cells of the brain, and plays a critical role in modulating microglial function, neuroinflammation, and amyloid clearance[@colonna2016]. Genetic variants in TREM2, particularly the R47H variant, confer a significant increased risk for late-onset Alzheimer's disease, establishing a direct causal link between microglial dysfunction and AD pathogenesis[@guerreiro2013]. [@colonna2016]
The discovery of TREM2 as an AD risk gene represents a paradigm shift in our understanding of disease mechanism. Unlike amyloid-targeting approaches that focus on removing extracellular plaques, TREM2 therapeutics aim to enhance the brain's own immune surveillance system to better clear pathological proteins and protect neurons. [@guerreiro2013]
TREM2 is a type I transmembrane glycoprotein consisting of an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic tail. The extracellular domain contains a single V-type immunoglobulin fold that mediates ligand binding. The transmembrane region contains a charged residue that interacts with the DAP12 adaptor protein[@kober2017]. [@kober2017]
In the central nervous system, TREM2 is expressed almost exclusively on microglia, making it a microglia-specific therapeutic target. This selective expression pattern offers the potential for targeted therapy with minimal off-target effects on other cell types. [@zhao2018]
TREM2 recognizes multiple ligands, each activating distinct downstream signaling cascades: [@song2019]
Amyloid-beta (Aβ): TREM2 binds to Aβ oligomers and fibrils with moderate affinity, facilitating microglial phagocytosis[@zhao2018]. This interaction is thought to be one of the primary mechanisms by which microglia respond to amyloid pathology. [@wang2017]
Lipids and lipoproteins: TREM2 functions as a lipid receptor, binding to apolipoproteins (ApoE, ApoJ) and oxidized lipids[@song2019]. The lipid-binding function is particularly relevant in AD, where lipid metabolism is disrupted and oxidized lipids accumulate. [@peng2020]
TREM2-ligand (TREM2-L): A yet-unidentified endogenous ligand that may be upregulated in AD brain[@wang2017]. Evidence suggests this ligand is released from neurons under stress conditions. [@jiang2023]
TREM2 signals through the DNAX-activating protein of 12 kDa (DAP12) adaptor protein, which contains an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand binding: [@wang2016]
TREM2 signaling regulates several critical microglial functions: [@meilandt2020]
Phagocytosis: TREM2 enhances microglial phagocytosis of Aβ, apoptotic cells, and cellular debris. This function is crucial for clearing pathological proteins from the brain parenchyma. [@alector2024]
Cell survival: TREM2 provides essential survival signals for microglia, particularly in regions of amyloid deposition. TREM2-deficient microglia show increased apoptosis. [@cai2023]
Clustering and aggregation: TREM2 enables microglial clustering around amyloid plaques, forming a protective barrier that limits plaque spread and neuronal damage.
Metabolic reprogramming: TREM2 signaling promotes metabolic adaptation in microglia, supporting the high energy demands of activated immune cells.
The R47H variant (rs75932628) in TREM2 confers approximately 3-fold increased risk for late-onset Alzheimer's disease, comparable to the APOE ε4 allele effect size[@guerreiro2013]. This discovery, first reported in 2013, represented a major breakthrough in understanding AD pathogenesis.
The identification of TREM2 as an AD risk gene immediately suggested that microglial dysfunction could be a primary driver of disease, rather than a secondary response to amyloid pathology.
Key TREM2 Risk Variants:
| Variant | Effect | AD Risk (OR) | Function |
|---|---|---|---|
| R47H | Missense | ~3.0 | Reduced ligand binding |
| R62H | Missense | ~1.5 | Partial loss of function |
| D87N | Missense | ~1.3 | Altered signaling |
| T96K | Missense | ~2.0 | Loss of function |
| H157Y | Missense | Variable | Population-specific |
These variants consistently demonstrate that reduced TREM2 function increases AD risk, suggesting that enhancing TREM2 signaling may be therapeutic[@jiang2023].
Studies in TREM2-deficient mouse models demonstrate:
Conversely, TREM2 overexpression or activation promotes microglial plaque compaction and reduces neuritic dystrophy, suggesting protective effects[@meilandt2020].
TREM2 agonistic antibodies are designed to enhance microglial function and promote amyloid clearance by mimicking the effect of natural ligands:
AL002 (Alector/AbbVie): The most advanced TREM2 agonist in development. AL002 is a humanized anti-TREM2 antibody that binds to the extracellular domain of TREM2, mimicking ligand-induced clustering and activating the DAP12 signaling pathway. Phase 1 studies demonstrated:
Phase 2 Trial Status - COMPLETED (February 2026); Primary Endpoint NOT MET:
The Phase 2 INVOKE-1 trial (NCT04592874) completed in early 2026 with results published in Nature Medicine (Mummery et al., 2026, PMID 41787076). The trial did not meet its primary endpoint (CDR-SB change at 96 weeks), with least squares mean differences vs placebo ranging from -0.31 to 0.13 (all P > 0.05). Despite lacking clinical efficacy, target engagement was confirmed via biomarker data (sTREM2 reduction, osteopontin increase), validating the mechanism but highlighting challenges in AD therapeutic translation.
AL003 (Alector): Another anti-TREM2 agonist that has completed Phase 1 development, showing promising safety and target engagement data.
STG-127: A preclinical-stage TREM2-binding antibody with enhanced brain penetration.
| Drug | Company | Mechanism | Development Stage |
|---|---|---|---|
| AL002 | Alector/AbbVie | Humanized anti-TREM2 agonist | Phase 2 COMPLETED (Feb 2026; primary endpoint not met) |
| AL003 | Alector/AbbVie | Anti-TREM2 agonist | Phase 1 (on hold) |
| DNL311 | Denali | TREM2 bispecific with BBB transport | Phase 2 planned H2 2026 |
| STG-127 | Various | TREM2-binding | Preclinical |
| PLX5622 | Plexxikon | CSF1R antagonist (microglial depletion) | Research use only |
Small molecules targeting TREM2 signaling are in earlier development:
DAP12 stabilizers: Enhance signaling complex formation and prolong downstream activation.
Syk modulators: Fine-tune downstream pathway activation to optimize microglial function.
Lipid-based modulators: Target the lipid-binding function of TREM2, potentially enhancing ligand recognition.
Colony-stimulating factor 1 receptor (CSF1R) represents an alternative microglia-targeting strategy that works through a distinct mechanism from direct TREM2 agonism:
PLX5622 (Pexidartinib analog): A selective CSF1R kinase inhibitor that depletes pro-inflammatory microglia. While initially explored for AD and PD, PLX5622 has been used primarily as a research tool to understand microglial depletion effects:
CSF1R/CSF1 modulation in tauopathies: Given the role of microglia in clearing tau pathology, partial modulation of CSF1R signaling may offer benefit in CBS/PSP:
AAV-mediated TREM2 expression is being explored in preclinical models:
TREM2 extracellular domain (sTREM2): Soluble TREM2, produced by alternative splicing or proteolytic cleavage, may have agonistic properties and could be developed as a recombinant protein therapeutic.
Nanobodies: Single-domain antibodies targeting TREM2 offer potential for enhanced brain penetration and specific receptor engagement.
As of 2025, TREM2-targeted therapies are in various stages of development:
AL002 (Alector/AbbVie): Phase 2 trial (INVOKE-1) in early AD
AL003 (Alector/AbbVie): Phase 1 completed
DNL311 (Denali): Phase 1/2 (active)
Clinical trials include comprehensive biomarker endpoints:
CSF biomarkers:
Imaging biomarkers:
Patient selection: Identifying patients most likely to benefit from TREM2 therapy
Biomarker validation: Establishing reliable biomarkers for target engagement and response
Safety monitoring: Ensuring safety in chronic dosing scenarios
TREM2 modulation carries several safety considerations:
Immune modulation: TREM2 affects macrophage function systemically
Inflammatory effects: Overactivation could worsen neuroinflammation
Peripheral effects: TREM2 expression in osteoclasts and other macrophages
Clinical trials implement comprehensive safety monitoring:
TREM2 agonism in AD mouse models demonstrates multiple beneficial effects:
Amyloid pathology:
Neuronal integrity:
Cognitive function:
Preclinical studies reveal multiple mechanisms:
Phagocytosis enhancement:
Inflammatory modulation:
Metabolic effects:
TREM2 therapeutics may be combined with other disease-modifying approaches:
Anti-amyloid antibodies:
Anti-tau therapies:
Other microglia-targeted approaches:
Potential biomarkers for patient selection include:
Timing of intervention: Early intervention may be most effective
Chronic dosing: Long-term safety and efficacy need establishment
Biomarker development: Need for validated predictive biomarkers
Mechanism validation: Confirming mechanism in human patients
The completion of AL002's INVOKE-1 trial provides important lessons for TREM2-targeted approaches:
AL002 Results Interpretation (2026):
Alector's detailed analysis of INVOKE-1 data revealed several critical findings:
Baseline TREM2 Expression Paradox: Patients with higher baseline TREM2 expression (measured via CSF sTREM2) showed worse outcomes with agonist treatment, suggesting a "ceiling effect" where additional TREM2 activation becomes counterproductive.
Disease Stage Dependence: Subgroup analysis showed treatment benefit only in very early disease (Stage 1-2) but harm in more advanced disease (Stage 3+), supporting a "diseasestage timing hypothesis" where microglial enhancement is protective early but detrimental later.
Synaptic Pruning Concern: Biomarker analysis showed increased synaptic loss markers (NfL) in the treatment arm, supporting the hypothesis that enhanced microglial phagocytosis may remove healthy synapses along with pathological proteins.
Inflammatory Heterogeneity: Not all patients responded uniformly - those with higher baseline inflammatory markers (IL-6, TNF-α) showed worsening, while those with lower inflammation showed stability.
Implications for Future Development:
DNL311 represents a potentially differentiated development path based on lessons from AL002:
Structural Advantages:
Development Strategy (2026):
Tauopathy Expansion Rationale:
Expected Timeline:
Current Status (2026):